原发性肝癌肝动脉化疗栓塞联合生物治疗的价值

目的 评价肝动脉化疗栓塞联合生物治疗对原发性肝癌的疗效。方法 56例原发性肝癌被随机分为两组:接受肝动脉化疗栓塞联合生物治疗的28例为观察组,只接受肝动脉化疗栓塞的28例为对照组。两组在治疗后半年、1年、2年的疗效与生存率分别作X~2检验,进行对照分析。结果 观察组的总有效率为67.8％(19/28)。而对照组为53.6％(15/28),两组间无显著性差异(X~2=1.20,P>0.05);半年、1年、2年时的生存率观察组分别为92.9％(26/28)、39.3％(11/28)和14.3％(4/28),而对照组分别为71.4％(20/28),14.3％(4/28)和0,两组分别比较有显著性差异(X~2值分别为4.38,4.46,4.30,P值均小于0.05)。结论 就原发性肝癌的保守治疗而言,肝动脉化疗栓塞联合生物治疗的效果期明显优于单纯肝动脉化疗栓塞。

The effect of hepatic artery embolism chemotherapy combined with biological therapy to treat primary liver cancer

Objective Evaluating the effect of hepatic artery embolism chemotherapy combined with biological therapy to treat primary liver cancer. Methods 56 patients with primary liver cancer were divided randomly into two groups i.e. 28 cases who received hepatic artery embolism chemotherapy combined with biological therapy were taken as an observing group and another 28 cases who received only hepatic artery embolism chemotherapy were taken as a control group.The therapeatic effects and survival rates at 1/2 years, 1 year and 2 years after the treatments in 2 groups were evaluated by X2 assays and comparative analyses. Results Total effective rate of observing group was 67.8 % ( 19/28 ) . Compared with 53.6 %( 15/28 ) of control group the difference had no significance (X2=1.20,P> 0.05). But the survival rates after 1/2 years ,1 year and 2 years of observing group were 92.9 % ( 26/28 ) ,39.3 % ( 11/28 ) and 14.3 % ( 4/28 ). Compared with 71.4 % ( 20/28), 14.3 % ( 4/28 )and 0 of control group, the difference was apparent (J2 values were 4.38, 4.46 and 4.30, respectively,P<0.05). Conclusion Hepatic artery embolism chemotherapy combined with biological therapy to treat primary liver cancer is very effective.